Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 PRESS RELEASE - Mawson Infrastructure Group Inc. | f8k090213_ex99z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) September 3, 2013
OphthaliX Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 000-52545 | 88-0445169 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
10 Bareket Street, Petach Tikva, Israel | 4951778 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: +(972) 3-9241114
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
. Written communications pursuant to Rule 425 under the Securities Act
. Soliciting material pursuant to Rule 14a-12 under the Exchange Act
. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 8.01
Other Events.
On September 3, 2013, OphthaliX, Inc., a Delaware corporation (the “Company”), issued a press release in regard to the issuance of a patent by the European Patent Office entitled “Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren's syndrome”. The patent was granted to the Company’s parent and majority stockholder, Can-Fite BioPharma Ltd., (“Can-Fite”), and relates to the Company’s drug candidate CF101. Pursuant to the license agreement between Can-Fite and the Company’s wholly owned subsidiary, EyeFite Ltd., this patent grants Ophthalix exclusive rights for the use of CF101 for the treatment of Sjogren's syndrome in Europe until 2025. A copy of the press release is included with this report.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
99.1
Press Release, dated September 3, 2013.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OphthaliX Inc.
Date: September 3, 2013
By /s/ Barak Singer
Barak Singer, Chief Executive Officer
2